newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Devdiscourse
Boehringer Ingelheim's survodutide led to average weight loss of up to 16.6% in a late-stage trial.
Boehringer Ingelheim's survodutide achieved 16.6% average weight loss in a Phase III obesity trial.
KEY POINTS
The SYNCHRONIZE-1 trial involved obese or overweight adults without type 2 diabetes.
Survodutide mimics both GLP-1 and glucagon hormones to potentially enhance weight loss effects.
Full Phase III results will be revealed at the American Diabetes Association's 2026 Scientific Sessions.
Boehringer Ingelheim said on Tuesday its experimental obesity drug led to average weight loss of up to 16.6% in a late-stage trial, as the unlisted German drugmaker seeks to catch up with obesity drug pioneers Eli Lilly and Novo Nordisk.
The Phase III trial showed patients treated with survodutide lost 16.6% of their body weight after 76 weeks, compared with 3.2% in a placebo group, Boehringer said in a statement. Participants were obese or overweight adults without type 2 diabetes.
Boehringer acquired the rights in 2011 to solely develop and commercialise survodutide from Denmark's Zealand Pharma, which is entitled to royalty payments on global revenue. Full results from the Phase III study, called SYNCHRONIZE-1, will be presented at the American Diabetes Association's 2026 Scientific Sessions, scheduled from June 5 to June 8.
Survodutide mimics the appetite-suppressing gut hormone GLP-1, targeted by injectable drugs such as Novo's Wegovy, but also imitates the gut hormone glucagon, a combination some developers hope will boost weight loss. Altimmune is developing a drug based on the effects of the same two hormones. In early 2024, survodutide delivered promising mid-stage results in the treatment of fatty liver, also known as metabolic dysfunction-associated steatohepatitis, or MASH.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)